Personalis, Inc. (FRA:04X)

Market Cap	527.24M +100.7%
Revenue (ttm)	59.32M -17.7%
Net Income	-69.22M
EPS	-0.78
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	25
Open	4.988
Previous Close	5.260
Day's Range	4.988 - 4.988
52-Week Range	3.018 - 9.760
Beta	n/a
RSI	41.60
Earnings Date	May 7, 2026

About Personalis

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2011
• Employees: 260
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 04X

Financial Performance

In 2025, Personalis's revenue was $69.65 million, a decrease of -17.69% compared to the previous year's $84.61 million. Losses were -$81.27 million, -0.02% less than in 2024.

Financial numbers in USD